Dr. Zornberg received her M.D. degree at the Columbia College of Physicians and Surgeons.  She completed her residency at McLean Hospital, where she was the Chief Resident of the Affective Disorders Program and a Fellow of the Group for the Advancement of Psychiatry on the Human Sexuality Committee.  Following her residency, Dr. Zornberg, completed an N.I.M.H. Training Grant in psychiatric epidemiology receiving master’s and doctoral degrees in epidemiology at the Harvard School of Public Health while serving at McLean Hospital as Psychopharmacology Fellow, then Psychiatrist-in-Chief of the McLean Hospital Alcohol and Drug Addiction Treatment Center partial Hospital.  She then became Director of Psychiatry Residency Education at the Massachusetts Mental Health Center and Associate Director for the Harvard Longwood Psychiatry Residency Training Program. During this time she published significant findings linking hypoxic-ischemic encephalopathy during fetal and neonatal brain development and risk in young adults of schizophrenia spectrum versus mood disorders or absence of mental illness.  Her work in pharmacoepidemiology encompasses big data analyses of adverse reactions of drugs used in psychiatry and neurology to work in the FDA contracted epidemiology sources leading first epidemiologic studies at FDA of pharmacogenetics modifying drug reactions or measuring efficacy of risk communications, and overseeing initiation and completion of the first FDA study contrasting and comparing computerized order entry approaches across electronic health record systems.  Her work in drug development focused most strongly on trials of drugs to treat depression, anxiety, or Alzheimer’s disease.Dr. Zornberg has been published on a broad variety of areas in Psychiatry, including papers on topics ranging from predictors of severe behavioral disorders to trials of drug efficacy.  She has written or co-written chapters in monographs on the bias against non-conforming gender orientation in the mental health professions, acute care of alcohol and drug abuse disorders to regulatory issues in drug development while a regulatory science team leader at the US FDA.  She presented clinical trial and methodological drug surveillance issues at psychiatry conferences, International pharmacoepidemiology conferences and American or European Drug Regulatory meetings.